Deferiprone

Deferiprone
Clinical data

Trade names	Ferriprox
AHFS/Drugs.com	International Drug Names
License data	EU EMA: Ferriprox US FDA: Deferiprone
Pregnancy category	US: D (Evidence of risk)
Routes of administration	Oral
ATC code	V03AC02 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Metabolism	Glucuronidation
Biological half-life	2 to 3 hours
Excretion	Renal (75 to 90% in 24 hours)
Identifiers
IUPAC name 3-hydroxy-1,2-dimethylpyridin-4(1H)-one
CAS Number	30652-11-0^Y
PubChem CID	2972
IUPHAR/BPS	7456
ChemSpider	2866^Y
UNII	2BTY8KH53L
KEGG	D07416^Y
ChEBI	CHEBI:68554^N
ChEMBL	CHEMBL70927^Y
ECHA InfoCard	100.157.470
Chemical and physical data
Formula	C₇H₉NO₂
Molar mass	139.152 g/mol
3D model (Jmol)	Interactive image
SMILES O=C\1C(\O)=C(/N(/C=C/1)C)C
InChI InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3^Y Key:TZXKOCQBRNJULO-UHFFFAOYSA-N^Y
^NY (what is this?)

Deferiprone (tradenames include Ferriprox) is a drug that chelates iron and is used to treat iron overload in thalassaemia major. It was first approved for use in treating thalassaemia major in 1994 and had been licensed for use in Europe and Asia for many years while awaiting approval in Canada and the United States. On October 14, 2011, it was approved for use in the US under the FDA’s accelerated approval program.

Deferiprone was at the center of a protracted struggle between Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and the pharmaceutical company Apotex, that started in 1996 and delayed approval of the drug in North America. Dr. Olivieri's data suggested deferiprone leads to progressive hepatic fibrosis.

...
Wikipedia